| Identification | Back Directory | [Name]
Tygacil | [CAS]
1229002-07-6 | [Synonyms]
TBG-MINO
Tigecyclin
Tigecycline hydrate
9-t-Butylglycylamido-minocycline hydrate
(4S,4aS,5aR,12aR)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide,hydrate | [Molecular Formula]
C29H41N5O9 | [MOL File]
1229002-07-6.mol | [Molecular Weight]
603.67 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMSO: ≥3mg/mL (warmed) | [form ]
powder | [color ]
off-white to yellow-brown | [Optical Rotation]
[α]/D -160 to 170°, c = 0.15 in methanol | [InChIKey]
PMPLAEFBZIFHAR-KXLOKULZSA-N | [SMILES]
O.CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)N(C)C |
| Hazard Information | Back Directory | [Uses]
Tigecycline hydrate, a glycylcycline antibiotic, used to treat infection by drug resistant bacteria such as Staphylococcus aureus (Staph aureus) and Acinetobacter baumannii. | [General Description]
Tigecycline is used to treat complicated skin and skin structure infections (cSSSI) and complicated intraabdominal infections. | [Biochem/physiol Actions]
Tigecycline is a broad spectrum glycylcycline antibiotic. Tigecycline is bacteriostatic, that inhibits protein synthesis by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation. Tigecycline is active against resistant strains of gram-positive and gram-negative bacteria, avoiding the two most common mechanisms of resistance to the tetracycline antimicrobials: tetracycline efflux pump proteins and ribosomal protection proteins. | [in vivo]
Tigecycline (50 mg/kg; intraperitoneal injection; twice a day; for 11 days) hydrate reduces tumor volume and weight in NOD/SCID mice[1].
The peak plasma concentration (Cmax), the terminal half-life (t1/2), area under the plasma concentration-time curve (AUC), clearance (CL) and volume of distribution (Vz) are 22.8μg/mL, 108.9 min, 1912.2min*μg/mL, 26.1 mL/min/kg, 4109.4 mL/kg for Tigecycline hydrate in saline, respectively[1]. | Animal Model: | NOD/SCID mice with OCI-AML2 acute myeloid leukemia (AML) xenograft model[1] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection; twice a day; for 11 days | | Result: | Reduced tumor volume and weight.
|
| Animal Model: | NOD/SCID mice[1] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection; 360 minutes | | Result: | The peak plasma concentration (Cmax), the terminal half-life (t1/2), area under the plasma concentration-time curve (AUC), clearance (CL) and volume of distribution (Vz) are 22.8 μg/mL, 108.9 min, 1912.2 min*μg/mL, 26.1 mL/min/kg, 4109.4 mL/kg, respectively.
|
|
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|